The increased abundance of HER2 activity in enzalutamide-resistant PCa cells raises the possibility that treatment with inhibitors against HER2 (or other RTK) may either increase tumor cell AR activity or enrich for the population of tumor cells that is harboring greater AR activity. The gene discussed is AR; the disease is neoplasm.